Click here to access the guidelines/NICE algorithm

N&WICS - TA809 - Imlifidase - Desensitisation treatment before kidney transplant in people with chronic kidney disease Before providing patient identifiable data on this form, please confirm that the patient (or in the case of a minor or vulnerable adult with the parent/legal guardian/carer) has given appropriate explicit consent for sensitive personal information on this form to be passed to the CCG and/or CSU for processing this funding request and validating subsequent invoices. Consent given: If there is more than one NICE-approved treatment available, a discussion between the responsible clinician and the patient has taken place about the advantages and disadvantages of the treatments available. This has taken into consideration therapeutic need and whether or not the patient is likely to adhere to treatment. The most appropriate, least expensive, will be chosen (taking into account administration costs, dosage and price per dose) unless an order of preference is stated in the TAs. **Patient Practice** Trust: NHS No: Name: **Patient** Consultant **Practice** Hospital Making Postcode: No. Request: Patient's **Practice** Initials and Code: DoB: Notification Contact Email (@NHS.net account ONLY) name & Address: number: Provider: Start date ☐ Private ☐ NHS of Supplier: Sub-Type: ☐ Homecare ☐ Hospital requested treatment: (if applicable) By completing this form, you confirm that you intend to use the requested medicinal product described below as agreed in the local commissioning statement. Any requests which fall outside of this use will require an individual funding request (IFR). For support regarding IFRs, please contact: norfolkicd@nhs.net For support regarding the criteria listed below, please contact: norfolknontariff@nhs.net Please tick Please indicate whether patient meets the following NICE criteria: 1. Imlifidase is recommended as a desensitisation treatment option for adults who: • are waiting for a kidney transplant from a deceased donor • are highly sensitised to human leukocyte antigens (HLA) • have a positive crossmatch with the donor and are unlikely to have a transplant under the available kidney ☐Yes ☐No allocation system (including prioritisation programmes for highly sensitised people).It is recommended only • a maximum of 1 dose is given • it is given in a specialist centre with experience of treating high sensitisation to HLA • the company provides imlifidase according to the commercial arrangement. 2. As per NICE guidance, treatment should normally be started with the least expensive drug (considering the dose required, price per dose and any additional administration costs). Please confirm that the choice of drug is considered the most cost-effective treatment for this individual patient, noting that alternative treatment options recommended by NICE may be lower in cost, including the ☐ Yes ☐ No use of biosimilar medications if applicable. Where an alternative lower cost treatment is available and has not been tried by the patient, please confirm that the clinical rationale for prescribing has been included in the patients' medical record for the purpose of I confirm that the patient meets the criteria for treatment Contact Details: Name of person completing:

Designation of person completing:	Date:
Trust Authorising Pharmacist	
Name: Date:	